AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
GlobalData on MSN11d
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third timeCharity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...
AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Three ...
SHANGHAI (Reuters) -AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare ...
The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback